Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Brain and Central Nervous System Tumors
Conditions: official terms
Brain Neoplasms - Central Nervous System Neoplasms - Nervous System Neoplasms
Conditions: Keywords
childhood low-grade cerebral astrocytoma, childhood craniopharyngioma, childhood central nervous system germ cell tumor, childhood high-grade cerebral astrocytoma, childhood oligodendroglioma, childhood choroid plexus tumor, childhood grade I meningioma, childhood grade II meningioma, childhood grade III meningioma, recurrent childhood cerebral astrocytoma, recurrent childhood medulloblastoma, recurrent childhood visual pathway and hypothalamic glioma, recurrent childhood ependymoma, recurrent childhood pineoblastoma
Study Type
Study Phase
Phase 2
Study Design
Masking: Open Label, Primary Purpose: Treatment
Name: antineoplaston A10 Type: Drug
Name: antineoplaston AS2-1 Type: Drug
Overall Status
RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.

PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating children with primary malignant brain tumors.
Detailed Description

- Determine the antitumor activity of antineoplastons A10 and AS2-1 in children with primary malignant brain tumors by determining the proportion of patients who experience an objective tumor response.

- Evaluate the adverse effects of and tolerance to this regimen in these children.

OUTLINE: This is an open-label study.

Patients receive gradually escalating doses of intravenous antineoplaston A10 and antineoplaston AS2-1 6 times daily until the maximum tolerated dose is reached. Treatment continues for at least 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients with responding or stable disease may continue treatment.

Tumors are measured every 8 weeks for 2 years, every 3 months for the third and fourth years, every 6 months for the fifth and sixth years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 17 Years
Minimum Age: N/A
Gender: Both

- Histologically confirmed incurable primary malignant brain tumor that has progressed, recurred, or persisted after initial therapy

- Must have failed prior standard therapy

- No brain stem glioma

- Evidence of tumor by MRI or CT scan



- 6 months to 17 years

Performance status:

- Karnofsky 60-100%

Life expectancy:

- At least 2 months


- WBC at least 1,500/mm^3

- Platelet count greater than 50,000/mm^3


- No hepatic failure

- Bilirubin no greater than 2.5 mg/dL

- SGOT/SGPT no greater than 5 times upper limit of normal


- Creatinine no greater than 2.5 mg/dL


- No severe heart disease

- No uncontrolled hypertension


- No severe lung disease


- Not pregnant or nursing

- Fertile patients must use effective contraception during and for 4 weeks after study participation

- No serious active infections or fever

- No other serious concurrent disease


Biologic therapy:

- At least 4 weeks since prior immunotherapy and recovered

- No concurrent immunomodulating agents


- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

- No concurrent antineoplastic agents

Endocrine therapy:

- Recovered from prior endocrine therapy

- Concurrent corticosteroids for cerebral edema allowed


- At least 8 weeks since prior radiotherapy (unless clear radiological evidence of progression) and recovered


- At least 4 weeks since prior surgery (unless clear radiological evidence of progression) and recovered


- No prior antineoplaston therapy
Burzynski Clinic
Houston, Texas, United States
Status: Recruiting
Contact: Stanislaw R. Burzynski, MD, PhD - 713-335-5697 -
Start Date
March 1996
Burzynski Research Institute
National Cancer Institute (NCI)
Record processing date processed this data on July 28, 2015 page